Search

Your search keyword '"Jaehde, U."' showing total 481 results
Start Over Author "Jaehde, U."
481 results on '"Jaehde, U."'

9. Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)

Author

Joerger, M., von Pawel, J., Kraff, S., Fischer, J.R., Eberhardt, W., Gauler, T.C., Mueller, L., Reinmuth, N., Reck, M., Kimmich, M., Mayer, F., Kopp, H.-G., Behringer, D.M., Ko, Y.-D., Hilger, R.A., Roessler, M., Kloft, C., Henrich, A., Moritz, B., Miller, M.C., Salamone, S.J., and Jaehde, U.

Published
2016
Full Text
View/download PDF

13. POLAR ‒ POLypharmazie, Arzneimittelwechselwirkungen und Risiken ‒ ein Zwischenbericht

Author

Loeffler, M, Neumann, D, Thalheim, T, Schmidt, F, Meineke, F, Kesselmeier, M, Maas, R, Thürmann, PA, Jaehde, U, Seidling, H, Fromm, MF, Dreischulte, T, Ganslandt, T, Scherag, A, POLAR-Team, Loeffler, M, Neumann, D, Thalheim, T, Schmidt, F, Meineke, F, Kesselmeier, M, Maas, R, Thürmann, PA, Jaehde, U, Seidling, H, Fromm, MF, Dreischulte, T, Ganslandt, T, Scherag, A, and POLAR-Team

Published
2023

17. Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib

Author

Diekstra, M.H.M., Swen, J.J., Zanden, L.F.M. van der, Vermeulen, S.H., Boven, E., Mathijssen, R.H., Fukunaga, K., Mushiroda, T., Hongo, F., Oosterwijk, E., Cambon-Thomsen, A., Castellano, D., Fritsch, A., Donas, J.G., Rodriguez-Antona, C., Ruijtenbeek, R., Radu, M.T., Eisen, T., Junker, K., Roessler, M., Jaehde, U., Miki, T., Böhringer, S., Kubo, M., Kiemeney, L.A.L.M., Guchelaar, H.J., Diekstra, M.H.M., Swen, J.J., Zanden, L.F.M. van der, Vermeulen, S.H., Boven, E., Mathijssen, R.H., Fukunaga, K., Mushiroda, T., Hongo, F., Oosterwijk, E., Cambon-Thomsen, A., Castellano, D., Fritsch, A., Donas, J.G., Rodriguez-Antona, C., Ruijtenbeek, R., Radu, M.T., Eisen, T., Junker, K., Roessler, M., Jaehde, U., Miki, T., Böhringer, S., Kubo, M., Kiemeney, L.A.L.M., and Guchelaar, H.J.

Abstract

Contains fulltext : 251723.pdf (Publisher’s version ) (Open Access), Individual response to sunitinib in metastatic renal cell carcinoma (mRCC) patients is highly variable. Earlier, sunitinib outcome was related to single nucleotide polymorphisms (SNPs) in CYP3A5 and ABCB1. Our aim is to provide novel insights into biological mechanisms underlying sunitinib action. We included mRCC patients from the European EuroTARGET consortium (n = 550) and the RIKEN cohort in Japan (n = 204) which were analysed separately and in a meta-analysis of genome-wide association studies (GWAS). SNPs were tested for association with progression-free survival (PFS) and overall survival (OS) using Cox regression. Summary statistics were combined using a fixed effect meta-analysis. SNP rs28520013 in PDLIM3 and the correlated SNPs rs2205096 and rs111356738 both in DSCAM, showed genome-wide significance (p < 5 × 10(-8)) with PFS and OS in the meta-analysis. The variant T-allele of rs28520013 associated with an inferior PFS of 5.1 months compared to 12.5 months in non-carriers (p = 4.02 × 10(-10), HR = 7.26). T-allele carriers of rs28520013 showed an inferior OS of 6.9 months versus 30.2 months in non-carriers (p = 1.62 × 10(-8), HR = 5.96). In this GWAS we identified novel genetic variants in PDLIM3 and DSCAM that impact PFS and OS in mRCC patients receiving sunitinib. The underlying link between the identified genes and the molecular mechanisms of sunitinib action needs to be elucidated.

Published
2022

19. 685P Genome-wide association meta-analysis identifies novel variants that correlate with efficacy outcomes in sunitinib-treated patients with metastatic renal cell carcinoma

Author

Diekstra, M., primary, Swen, J., additional, van der Zanden, L., additional, Vermeulen, S., additional, Boven, E., additional, Mathijssen, R.H., additional, Oskarsdottir, A., additional, Oosterwijk, E., additional, Cambon-Thomsen, A., additional, Castellano, D., additional, Fritsch, A., additional, Garcia-Donas, J., additional, Rodriguez-Antona, C., additional, Jaehde, U., additional, Rafnar, T., additional, Stefansson, K., additional, Bohringer, S., additional, Kubo, M., additional, Kiemeney, L., additional, and Guchelaar, H-J., additional

Published
2021
Full Text
View/download PDF

30. Needs assessment for an interprofessional academic program for medication safety

Author

Thevissen, J, Böhmer, A, Al Ghaddioui, R, Olejniczak, K, Dartsch, D, Hänisch, B, Laven, A, Mahler, C, Paeschke, N, Seidling, H, Weltermann, B, Woltersdorf, R, and Jaehde, U

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Background: An academic program on medication safety may enhance education and training of multiplicators sensitizing health care professionals for patients’ medication risks. Such a program may systematically minimize medication risks in routine health care. Aim of this project is to assess [for full text, please go to the a.m. URL], 26. Jahrestagung der Gesellschaft für Arzneimittelanwendungsforschung und Arzneimittelepidemiologie

Published
2019
Full Text
View/download PDF

32. Abstracts of papers and posters advanced activities in pharmaceutical care 24th European Symposium on Clinical Pharmacy

Author

Nahata, M. C., Bootman, J. L., Zadák, Z., Soeters, P. B., Goldberg, Laurence A., Stremetzne, S., Jaehde, U., Streit, M., Kreuser, E. D., Thiel, E., Schunack, W., Calvert, R. T., Feely, M., Chrystyn, H., Mangues M. A., Ginovart G., Moral M. A., Lopes A. P., Farré R., Demestre X., Altirriba O., Kloft, Ch., Beyer, J., Steuer, J., Siegert, W., Bever, J., Bialer, M., Sussan, S., Salach, O. Abu, Danenberg, H. D., Laor, A., Barnett, M. I., Cosslett, A. G., Cohen, J., Marini, P., Bassi, C., Bonzanini, A., Cassani, T., Dalle Ore, G., Mangiante, G., Scroccaro, G., Kaczan, M., Eriksen, J., Toft, B., Jandová, M., Vlček, J., Klemerová, V., Sobotka, L., Ayestarán A., López R., Montoro J. B., Pou L., Estíbalez A., Pascual B., Aumente M. D., Panadero M. D., Caraballo M., Pozo J. C., Perez J. L., Falcão, A. C., Fernández de Gatta, M. M., Dominguez-Gil, A., Caramona, M. M., Lanao, J. M., Fendrich, Z., Zajic, J., Bellés Medall M. D., Casabó Alós V. G., Jiménez Torres N. V., Hervás Botella M. A., Abad Gimeno F. J., Casterá Melchor D. E., Aminian M., Mangues M. A., Clopés A., Branco C., Badell I., Pardo, N., Palací C., Bonal J., Rialp G., Bara B., Nobilis, M., Bláha, V., Havel, E., Květina, J., Brátová, M., Solichová, D., Mullerova, M., Svoboda, D., Pokrajac, M., Miljković, B., Simić, D., Brzaković, B., Galetin, A., Pinheiro, R. L., Carrondo, A. P., Sieradzki, E., Strauss, K., Olejarz, E., Marzec, A., Kaużny, J., Szymura-Oleksiak, J., Wyska, E., Jarosz, B., Kosowicz, I., Fabirkiewicz, K., Cherian, R., Vodoz, A. -L., Imsand, B., Belli, D., Rochat, Th., Müllerová, H., Falcão F., Carvalho A., Pereira T., Fonseca C., Freitas O., Resende M., Parrinha A., Costa M., Pessanha M. A., Ferreira A., Mourão L., Ceia F., Lima, Mendonça, Tavares R., SalesLuis A., Carlos Santos, Pereira, M. E. Araújo, Carmo, J. Alves do, Lacerda, J. M. Forjaz, Morais, J. A., Beaufils, C., Le Duff, M., Zamparutti, P., Assicot, P., Bohor, M., Angelini, B., Lambert, M., Manelli, J. C., Gayte-Sorbier, A., Bongrand, M. C., Timon-David, P., Fiqueira, I. C., Lourenco, R., Silva, P. A., Rodrigues, M. O., Fischer, A., Schorr, W., Radziwill, R., Lihtamo M., Jäppinen A., Tuovinen K., Pekkala M., Nuutinen L., Morató, L., Lorente, L., Muñoz, J., Monges, Ph, Blancard, A., Lacarelle, B., Denis, J. P., Bongrand, M. -C., Penot-Ragon, Ch, Gouin, F., Petitcollot, Nicole, Tinguely, I., Beney, J., Marty, S., Reymond, J. -Ph., Bussels J., Robays H., Litzinger, A., Rohda-Bohler, R., Salek, M. S., Turpin, S., Derby, E., Millar, B., Maggs, C., Santiago L. M., Batel Marques, Cajaraville, G., Tarnés, M. J., Díaz, M. J., Del Pozo, C., Plazaola, A., Vuelta, M., Díaz-Munío, E., Ferrer, A., Lozano, A., Guerra, R., Pontón, J. L., Robays, H., Kint, K., Verstraetep, A., Eini, D. El, Ojala, R. K., Kontra, K. M., Naaranlahti, T. J. P., Martorell M., Oliveras M., Juste C., Lopez M. T., Hidalgo E., Cabañas M. J., Barroso C., Llop, J. M., Rey, M., Diaz-Munio, E., Pastó, L., Tubau, M., Gómez-Bellver, M. J., Rodriguez, J., Gómez, J. M., Gónzalez, M. L., Gol V., Fuentes V., Ramón S., Girona L., Castelló T., Olona M., García L., Girón, C., Monteserín, C., Gonzalez, P., Alberola, C., Feio J. A. L., Pharm D., Batel Marques F. J., Borges Alexandrino M., Salek S., Escoms M. C., Caro I., Ticó N., Hidalgo M., Bruguera R., Jodar R., Dowell, J. M., Davey, P. G., Malek, M., Díaz-Munío, E., Vuelta, M., Pastó, L., Rev, M., Ferrer, I., Llop, J. M., Marti, T., Ibars, M., Delporte, J. P., Ansseau, M., Albert, A., Sibourg, M., Gaspard, O., Deprez, M., Ndougsa, H. M., Poma, M., Tamés, M. J., Macek K., Vlček J., Fendrich Z., Klejna M., Dhillon S., Castro I., Newton M., Zupanets, I. A., Chernyh, V. P., Bezdetko, N. B., Popov, S. B., Velieva, M. N., Babajeya, S. M., Mamedov, Y. D., Mammedov, Y. Dj., Veliev, P. M., Nasudari, A. A., Bandalieva, A. A., Nordbo, S., Smith-Solbakken, M., Myklctun, R., Berge, W., Thormodsen, M., Zupanets, L. A., Kicenko, L. S., Plusch, S. I., Isaev, S. G., Vokrouhlický, L., Souček, R., Kuneš, P., Nývlt, O., Potselueva, L. A., Egorova, S. N., Kadirova, E. A., Ziganshina, L. E., Chaloupka, J., and Genger K.

Published
1995
Full Text
View/download PDF

38. Using failure mode and effects analysis to increase patients’ safety in chemotherapy

Author

Weber, L, Schulze, I, and Jaehde, U

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Background: Ensuring the safety of patients in high-risk processes, e.g., chemotherapy, is a challenging task. Medication errors may occur during chemotherapy and could have fatal consequences. Healthcare Failure Mode and Effects Analysis (FMEA) is a method used to detect potential risks and prevent[for full text, please go to the a.m. URL], 25. Jahrestagung der Gesellschaft für Arzneimittelanwendungsforschung und Arzneimittelepidemiologie

Published
2018
Full Text
View/download PDF

39. Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer

Author

Diekstra, M.H., Fritsch, A., Kanefendt, F., Swen, J.J., Moes, D.J.A.R., Sorgel, F., Kinzig, M., Stelzer, C., Schindele, D., Gauler, T., Hauser, S., Houtsma, D., Roessler, M., Moritz, B., Mross, K., Bergmann, L., Oosterwijk, E., Kiemeney, L.A., Guchelaar, H.J., Jaehde, U., MUMC+: DA KFT Medische Staf (9), and RS: FHML non-thematic output

Subjects
BIOMARKER, Adult, Male, Vascular Endothelial Growth Factor A, ATP Binding Cassette Transporter, Subfamily B, Indoles, Genotype, ACTIVE METABOLITE, SU11248, Medizin, Antineoplastic Agents, METABOLITE SU12662, urologic and male genital diseases, Models, Biological, Polymorphism, Single Nucleotide, RENAL-CELL CARCINOMA, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Sunitinib, Cytochrome P-450 CYP3A, Humans, Pyrroles, ddc:610, Carcinoma, Renal Cell, Protein Kinase Inhibitors, Aged, Aged, 80 and over, Interleukin-8, SINGLE-NUCLEOTIDE POLYMORPHISMS, Original Articles, Middle Aged, Vascular Endothelial Growth Factor Receptor-3, Vascular Endothelial Growth Factor Receptor-2, Kidney Neoplasms, 1ST-LINE SUNITINIB, Treatment Outcome, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], ENDOTHELIAL GROWTH-FACTOR, Original Article, Female, INTERFERON-ALPHA, Colorectal Neoplasms, HEALTHY-VOLUNTEERS
Abstract

Contains fulltext : 177889.pdf (Publisher’s version ) (Open Access) The tyrosine kinase inhibitor sunitinib is used as first-line therapy in patients with metastasized renal cell carcinoma (mRCC), given in fixed-dose regimens despite its high variability in pharmacokinetics (PKs). Interindividual variability of drug exposure may be responsible for differences in response. Therefore, dosing strategies based on pharmacokinetic/pharmacodynamic (PK/PD) models may be useful to optimize treatment. Plasma concentrations of sunitinib, its active metabolite SU12662, and the soluble vascular endothelial growth factor receptors sVEGFR-2 and sVEGFR-3, were measured in 26 patients with mRCC within the EuroTARGET project and 21 patients with metastasized colorectal cancer (mCRC) from the C-II-005 study. Based on these observations, PK/PD models with potential influence of genetic predictors were developed and linked to time-to-event (TTE) models. Baseline sVEGFR-2 levels were associated with clinical outcome in patients with mRCC, whereas active drug PKs seemed to be more predictive in patients with mCRC. The models provide the basis of PK/PD-guided strategies for the individualization of anti-angiogenic therapies.

Published
2017

43. Schwangerschaft und Stillzeit

Author

Jaehde, U, Radziwill, R, Kloft, C, Jaehde, U ( U ), Radziwill, R ( R ), Kloft, C ( C ), von Mandach, U, Jaehde, U, Radziwill, R, Kloft, C, Jaehde, U ( U ), Radziwill, R ( R ), Kloft, C ( C ), and von Mandach, U

Published
2010

44. Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity

Author

Zanden, L.F.M. van der, Vermeulen, S.H., Oskarsdottir, A., Maurits, JSF, Diekstra, M.H.M., Ambert, V., Cambon-Thomsen, A., Castellano, D., Fritsch, A., Garcia Donas, J., Guarch Troyas, R., Guchelaar, H.J., Hartmann, A., Hulsbergen-van de Kaa, C.A., Jaehde, U., Junker, K., Martinez-Cardus, A., Masson, G., Oosterwijk-Wakka, J., Radu, M.T., Rafnar, T., Rodriguez-Antona, C., Roessler, M., Ruijtenbeek, R., Stefansson, K., Warren, A., Wessels, L., Eisen, T., Kiemeney, L.A., Oosterwijk, E., Zanden, L.F.M. van der, Vermeulen, S.H., Oskarsdottir, A., Maurits, JSF, Diekstra, M.H.M., Ambert, V., Cambon-Thomsen, A., Castellano, D., Fritsch, A., Garcia Donas, J., Guarch Troyas, R., Guchelaar, H.J., Hartmann, A., Hulsbergen-van de Kaa, C.A., Jaehde, U., Junker, K., Martinez-Cardus, A., Masson, G., Oosterwijk-Wakka, J., Radu, M.T., Rafnar, T., Rodriguez-Antona, C., Roessler, M., Ruijtenbeek, R., Stefansson, K., Warren, A., Wessels, L., Eisen, T., Kiemeney, L.A., and Oosterwijk, E.

Abstract

Contains fulltext : 177333.pdf (publisher's version ) (Open Access), OBJECTIVE: For patients with metastatic renal cell cancer (mRCC), treatment choice is mainly based on clinical parameters. With many treatments available and the limited response to treatment and associated toxicities, there is much interest in identifying better biomarkers for personalized treatment. EuroTARGET aims to identify and characterize host- and tumor-related biomarkers for prediction of response to tyrosine kinase inhibitor therapy in mRCC. Here, we describe the EuroTARGET mRCC patient cohort. METHODS AND MATERIALS: EuroTARGET is a European collaborative project designed as an observational study for which patients with mRCC were recruited prospectively in 62 centers. In addition, 462 patients with mRCC from previous studies were included. Detailed clinical information (baseline and follow-up) from all patients was entered in web-based case record forms. Blood was collected for germline DNA and pharmacokinetic/pharmacodynamic analyses and, where available, fresh-frozen tumor material was collected to perform tumor DNA, RNA, kinome, and methylome analyses. RESULTS: In total, 1,210 patients with mRCC were included. Of these, 920 received a tyrosine kinase inhibitor as first-line targeted treatment (sunitinib [N = 713, 78%], sorafenib [N = 41, 4%], or pazopanib [N = 166, 18%]) and had at least 6 months of outcome assessment (median follow-up 15.3 months [interquartile range: 8.5-30.2 months]). Germline DNA samples were available from 824 of these patients, fresh-frozen tumor material from 142 patients, fresh-frozen normal kidney tissue from 95 patients, and tissue microarrays created from formalin-fixed paraffin-embedded tumor material from 247 patients. Of the 920 patients, germline DNA variant chip data were successfully generated for 811 patients (Illumina HumanOmniExpress BeadChip). For 80 patients, next-generation exome sequencing of germline and tumor DNA was performed, tumor RNA sequencing was performed for 124 patients, kinome activity measured and p

Published
2017

45. Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer

Author

Diekstra, M.H.M., Fritsch, A., Kanefendt, F., Swen, J.J., Moes, D., Sorgel, F., Kinzig, M., Stelzer, C., Schindele, D., Gauler, T., Hauser, S., Houtsma, D., Roessler, M., Moritz, B., Mross, K., Bergmann, L., Oosterwijk, E., Kiemeney, L.A.L.M., Guchelaar, H.J., Jaehde, U., Diekstra, M.H.M., Fritsch, A., Kanefendt, F., Swen, J.J., Moes, D., Sorgel, F., Kinzig, M., Stelzer, C., Schindele, D., Gauler, T., Hauser, S., Houtsma, D., Roessler, M., Moritz, B., Mross, K., Bergmann, L., Oosterwijk, E., Kiemeney, L.A.L.M., Guchelaar, H.J., and Jaehde, U.

Abstract

Contains fulltext : 177889.pdf (publisher's version ) (Open Access), The tyrosine kinase inhibitor sunitinib is used as first-line therapy in patients with metastasized renal cell carcinoma (mRCC), given in fixed-dose regimens despite its high variability in pharmacokinetics (PKs). Interindividual variability of drug exposure may be responsible for differences in response. Therefore, dosing strategies based on pharmacokinetic/pharmacodynamic (PK/PD) models may be useful to optimize treatment. Plasma concentrations of sunitinib, its active metabolite SU12662, and the soluble vascular endothelial growth factor receptors sVEGFR-2 and sVEGFR-3, were measured in 26 patients with mRCC within the EuroTARGET project and 21 patients with metastasized colorectal cancer (mCRC) from the C-II-005 study. Based on these observations, PK/PD models with potential influence of genetic predictors were developed and linked to time-to-event (TTE) models. Baseline sVEGFR-2 levels were associated with clinical outcome in patients with mRCC, whereas active drug PKs seemed to be more predictive in patients with mCRC. The models provide the basis of PK/PD-guided strategies for the individualization of anti-angiogenic therapies.

Published
2017

49. Population pharmacokinetic model for cisplatin during intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC) in patients with platinum-sensitive recurrent epithelial ovarian cancer (EOC)

Author

Fritsch, A., Kullmann, M., Zivanovic, O., Abramian, A., Hilger, R., Kuhn, W., and Jaehde, U.

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Aim: Epithelial ovarian cancer is the leading cause of death from a gynaecologic malignancy. Because the natural history of the disease is mostly confined to the peritoneal cavity, hyperthermic intraperitoneal chemoperfusion (HIPEC) has a strong rationale as treatment option. It was the aim of this [for full text, please go to the a.m. URL], 16. Jahreskongress für Klinische Pharmakologie

Published
2014

50. Novel Approaches for Dose Individualization in Anti-Cancer Drug Therapy [invited speaker]

Author

Jaehde, U.

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Aim: Individualized therapies have gained growing interest in oncology. Pharmacogenetic and pharmacogenomic approaches are often proposed to select the best individual treatment for the patient. However, appropriate drug dosing is also crucial for an effective and safe therapy. In oncology, the dosage[for full text, please go to the a.m. URL], 16. Jahreskongress für Klinische Pharmakologie

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results